Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
300006.SZ
SELLChongqing Lummy Pharmaceutical Co., Ltd. · Healthcare · China · $698M · Avg Vol: $22M/d
33
StockRankGet insider-trade alerts
Q
40
V
26
M
59
P/E (TTM)
—
ROE
-6.9%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 130.3M | 131.9M | 117.2M | 114.2M | -4.3% | 111.9M |
| EPS | -0.01 | -0.00 | -0.01 | -0.02 | — | -0.02 |
| Shares | 1.1B | 1.1B | 1.1B | 1.1B | 0.0% | 1.1B |
| Debt | 53.8M | 39.9M | 72.8M | 55.0M | 0.7% | 58.4M |
| Equity | 312.9M | 306.4M | 276.2M | 258.6M | -6.2% | — |
| Op CF | 8.4M | 12.0M | 27.3M | 3.8M | -23.0% | 5.1M |
| Inv CF | 2.0M | -18.7M | -2.7M | -7.6M | — | — |
| Fin CF | 24.5M | -12.0M | 28.0M | -17.4M | — | — |
Loading 1Y...
PRICE (1Y)-9.3%
SMA 50SMA 200
Close
$0.7143
RSI (14)
55.2
52W High
$1.01
From 52W High
0.7%
SCORE BREAKDOWN
Quality
40
ROIC
-7.2%36.8
ROE
-6.9%37.5
GP/Assets
15.8%37.6
Op. Margin
-3.0%32.9
FCF/Assets
1.4%50.9
Piotroski
548.9
Int. Cover
-9.7x22.8
D/E Ratio
0.23x50.6
Current Ratio
2.01x38.0
Value
26
P/E (TTM)
—N/A
EV/EBITDA
-158.3x25.0
P/FCF
133.0x9.7
P/B
3.0x45.0
P/S
6.8x34.0
Div Yield
—N/A
Momentum
59
52W High %
71%52.1
RS 6M
-11%57.6
SMA 50/200
1.05x75.9
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+223%89.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$698M
P/E (Forward)
30.5x
Gross Margin
53.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300006.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 300006.SZ | Chongqing Lummy Pharmaceutical Co., Ltd.(you) | $698M | 33 | SELL |
| 301507.SZ | Hangzhou Minsheng Healthcare Co., Ltd. | $633M | 44 | HOLD |
| 301096.SZ | Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. | $961M | 21 | SELL |
| 600771.SS | GuangYuYuan Chinese Herbal Medicine Co., Ltd. | $916M | 48 | HOLD |
| 002019.SZ | Yifan Pharmaceutical Co., Ltd. | $1.7B | 38 | HOLD |
| 600666.SS | Aurora Optoelectronics Co.,Ltd. | $1.7B | 25 | SELL |
| 7630.HK | IMPACT THERAP-B | $1.3B | 8 | STRONG SELL |
| 1643.HK | Modern Chinese Medicine Group Co., Ltd. | $127M | 37 | HOLD |
| 2630.HK | Vigonvita Life Sciences Co., Ltd. | $1.3B | 3 | STRONG SELL |
| 688710.SS | Shanghai InnoStar Bio-tech Co., Ltd. | $1.3B | 62 | HOLD |
Peer medians: ROE 4.7% · P/E 28.4x · Gross margin 52.5%